Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
-
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
Developing a blueprint to overcome challenges in implementing new payment models will ensure better access.
Categorized in -
Approval and Reimbursement of Alzheimer’s Disease Therapies
On Monday, June 6, join the Schaeffer Center for a discussion about the regulatory challenges of approving and reimbursing therapies for Alzheimer’s disease.
-
Estimating the Value of Diagnosing and Treating Alzheimer’s Disease
On May 9, join a Schaeffer Center seminar to discuss improving access to new treatments, identifying the size of the treatment-eligible population, the need for affordable diagnostic tests, and how innovation could help pay for diagnostics and treatments to ensure the healthcare system has the capacity and resources to treat everyone in need.
-
Leveraging Alzheimer’s Disease Clinical Trial Outcomes in Health Economics Research
Join the Schaeffer Center for an academic seminar on the implications of clinical trial design on Alzheimer’s disease modeling.
-
Impact of Non-Binding FDA Guidances On Primary Endpoint Selection in Alzheimer’s Disease Trials
Researchers examine the impact of two guidance documents for Alzheimer’s disease (AD) trials. The first guidance in 2013 encouraged the use of cognitive/functional endpoints, while the second in 2018 modified such recommendation.
-
Barriers to Seeking Care for Memory Problems: A Vignette Study
Abstract Introduction: This study compares how older adults judge the need for follow-up care for memory-related problems when they are responding about themselves versus someone of the same age. Methods: Adults ages 65 and over in the Understanding America Study, a nationally representative internet panel, were invited to participate in a short survey with three […]
Categorized in -
The Rising Burden of Alzheimer’s Disease Mortality in Rural America
Since the 1990s, there has been a striking urban-rural divergence in life expectancy within the United States, with metropolitan areas achieving strong life expectancy increases and nonmetropolitan areas experiencing stagnation or actual declines in life expectancy.
-
Global Projections of Dementia: United States, Ireland, Japan and Mexico
On March 9, join a webinar on projections of population-level cognitive impairment and dementia in the US, Ireland, Japan, and Mexico. The panel will also discuss how simulation modeling can be used for projecting costs and health outcomes of new therapeutics for AD/ADRD.
-
Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
Schaeffer Center researchers have found older Americans know little about aducanumab, despite the fact that an overwhelming majority of survey respondents said they were worried about Alzheimer’s disease.
-
Study Finds Older Americans Are Largely Unaware of a New Alzheimer’s Drug
Among older Americans surveyed in the weeks after FDA approval of aducanumab, few could correctly answer true or false questions about the first new Alzheimer’s drug in decades.